Andrea Necchi presents GDFATHER-NEO trial results, evaluating neoadjuvant nivolumab plus visugromab versus nivolumab-placebo in 31 cisplatin-ineligible/refusing muscle-invasive bladder cancer patients ...

Prostate Cancer Mortality Among Men with and Without Comorbidity: Long-Term Results from the European Randomized Study of Screening for Prostate Cancer Rotterdam - Beyond the Abstract ...

Juan Ruiz-Bañobre presents an ultrasensitive ctDNA analysis in advanced clear cell RCC, using a tumor-informed whole genome sequencing assay on serial plasma samples from 37 treatment-naive patients ...

Pedro Barata discusses systemic therapy selection and monitoring in low-volume metachronous metastatic hormone-sensitive prostate cancer. He emphasizes that low disease volume doe ...

Yudai Ishiyama presents a restricted mean survival time analysis of four IO combination regimens in advanced clear cell RCC. Using digitized Kaplan-Meier data from CheckMate 214, ...

Treating Lower Urinary Tract Symptoms in Older Adults: Intravesical Options - Beyond the Abstract ...

(UroToday.com) The 2026 American Society of Clinical Oncology Genitourinary (ASCO) Annual Meeting held in Chicago, IL, was host to the Prostate, Testicular, and Penile Cancer - Rapid Oral Abstracts ...

(UroToday.com) The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting was host to a kidney and bladder cancers poster session. Dr. Robert Motzer presented the final analysis of the ...

(UroToday.com) The 2026 ASCO annual meeting featured a prostate cancer trials in progress session and a presentation by Dr. Donald Vile discussing OMAHA-004, a phase 3 trial of steroidogenesis ...

AUA 2026, BCG naive and BCG-Exposed High-Risk Non–muscle Invasive Bladder Cancer, Intravesical MK-3120, anti–Nectin-4 monoclonal antibody, MK-3120 I-VESIC.

AUA 2026 high-risk non-muscle invasive bladder cancer with papillary carcinoma or CIS, AUA AQUA Registry, National Cancer Institute SEER registry.

(UroToday.com) The 2026 Advanced Prostate Cancer Consensus Conference (APCCC) meeting featured a high-risk and locally advanced prostate cancer session and a presentation by Dr. Jason Efstathiou ...